BAP1 and neoplasm: The performance of the RFC is assessed by the LOOCV procedure, and the F1-scores were 0.60, 0.00, and 0.00 for patients harboring a BAP1, SF3B1, and EIF1AX-mutated tumor in the negative ion mode, respectively; and 0.53, 0.00, and 0.00 for patients harboring a BAP1, SF3B1, and EIF1AX-mutated tumor in the positive ion mode, respectively (Table 3A).